Publication date: Sep 19, 2023
To evaluate the impact of telehealth use during the COVID-19 pandemic on glycaemic control and other clinical outcomes among patients with type 2 diabetes. We used electronic health records from the Research Action for Health Network (REACHnet) database for patients with type 2 diabetes who had telehealth visits and those who only received in-person care during the pandemic. A quasi-experimental method of difference-in-difference with propensity-score weighting was implemented to mitigate selection bias and to control for observed factors related to telehealth use. Outcomes included glycated haemoglobin (HbA1c) and other clinical measures (low-density lipoprotein [LDL] cholesterol, blood pressure [BP], and body mass index [BMI]). Patients using telehealth had better HbA1c control compared to those receiving in-person care only during the pandemic. The telehealth group saw a significant average decrease of 0. 146% (95% confidence interval [CI] -0. 178% to -0. 1145%; P 7% decreased by 0. 023 (95% CI -0. 034, -0. 011; P
| Concepts | Keywords |
|---|---|
| Confidence | cohort study |
| Diabetes | effectiveness |
| Lipoprotein | glycaemic control |
| Pandemic | primary care |
| real-world evidence | |
| type 2 diabetes |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | type 2 diabetes |
| disease | MESH | COVID-19 pandemic |
| drug | DRUGBANK | Cholesterol |
| disease | IDO | blood |
| drug | DRUGBANK | Tropicamide |
| disease | VO | effectiveness |